Bio-Techne Corporation (TECH)
NASDAQ: TECH · Real-Time Price · USD
54.02
+1.52 (2.90%)
At close: Jun 11, 2026, 4:00 PM EDT
54.02
0.00 (0.00%)
After-hours: Jun 11, 2026, 4:03 PM EDT
Bio-Techne Employees
Bio-Techne had 3,100 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
3,100
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$390,584
Profits / Employee
$35,322
Market Cap
8.46B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 3,100 | 0 | - |
| Jun 30, 2024 | 3,100 | 50 | 1.64% |
| Jun 30, 2023 | 3,050 | 50 | 1.67% |
| Jun 30, 2022 | 3,000 | 400 | 15.38% |
| Jun 30, 2021 | 2,600 | 300 | 13.04% |
| Jun 30, 2020 | 2,300 | 50 | 2.22% |
| Jun 30, 2019 | 2,250 | 250 | 12.50% |
| Jun 30, 2018 | 2,000 | 200 | 11.11% |
| Jun 30, 2017 | 1,800 | 240 | 15.38% |
| Jun 30, 2016 | 1,560 | 204 | 15.04% |
| Jun 30, 2015 | 1,356 | 335 | 32.81% |
| Jun 30, 2014 | 1,021 | 167 | 19.56% |
| Jun 30, 2013 | 854 | 7 | 0.83% |
| Jun 30, 2012 | 847 | 13 | 1.56% |
| Jun 30, 2011 | 834 | 97 | 13.16% |
| Jun 30, 2010 | 737 | -9 | -1.21% |
| Jun 30, 2009 | 746 | 27 | 3.76% |
| Jun 30, 2008 | 719 | 38 | 5.58% |
| Jun 30, 2007 | 681 | 44 | 6.91% |
| Jun 30, 2006 | 637 | 28 | 4.60% |
| Jun 30, 2005 | 609 | 12 | 2.01% |
| Jun 30, 2004 | 597 | 11 | 1.88% |
| Jun 30, 2003 | 586 | 16 | 2.81% |
| Jun 30, 2002 | 570 | 9 | 1.60% |
| Jun 30, 2001 | 561 | 64 | 12.88% |
| Jun 30, 2000 | 497 | 26 | 5.52% |
| Jun 30, 1999 | 471 | 60 | 14.60% |
| Jun 30, 1998 | 411 | 46 | 12.60% |
| Jun 30, 1997 | 365 | -7 | -1.88% |
| Jun 30, 1996 | 372 | 28 | 8.14% |
| Jun 30, 1995 | 344 | 67 | 24.19% |
| Jun 30, 1994 | 277 | 71 | 34.47% |
| Jun 30, 1993 | 206 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Corcept Therapeutics | 730 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 691 |
| Cytokinetics | 673 |
| Halozyme Therapeutics | 423 |
| Krystal Biotech | 295 |
| Summit Therapeutics | 265 |
| Nuvalent | 234 |
TECH News
- 10 hours ago - Bio-Techne initiated with a Neutral at Piper Sandler - TheFly
- 7 days ago - Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization - PRNewsWire
- 27 days ago - Bio-Techne resumed with an Outperform at RBC Capital - TheFly
- 4 weeks ago - Bio-Techne Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Bio-Techne price target lowered to $66 from $75 at Deutsche Bank - TheFly
- 5 weeks ago - Bio-Techne price target lowered to $49 from $70 at Baird - TheFly
- 5 weeks ago - Bio-Techne price target lowered to $50 from $65 at Stifel - TheFly
- 5 weeks ago - Bio-Techne price target lowered to $50 from $54 at Evercore ISI - TheFly